Medical advances with international impact.
James
J S
JS
D017088:AIDS-Related Opportunistic Infections / Q000517:prevention & control*; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D000904:Antibiotics, Antitubercular / Q000627:therapeutic use*; D000995:Antitubercular Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003906:Developing Countries; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000097:blood* / Q000517:prevention & control / Q000635:transmission*; D006297:Health Services Accessibility; D006801:Humans; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D007538:Isoniazid / Q000627:therapeutic use*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious; D011718:Pyrazinamide / Q000627:therapeutic use*; D012367:RNA, Viral / Q000097:blood*; D011933:Reagent Kits, Diagnostic; D012293:Rifampin / Q000627:therapeutic use*; D014376:Tuberculosis / Q000517:prevention & control*; D019562:Viral Load / Q000379:methods*; D015215:Zidovudine / Q000627:therapeutic use*
D019380:Anti-HIV Agents; D000904:Antibiotics, Antitubercular; D000995:Antitubercular Agents; D012367:RNA, Viral; D011933:Reagent Kits, Diagnostic; D011718:Pyrazinamide; D015215:Zidovudine; D007538:Isoniazid; D012293:Rifampin